Immune Biosolutions has announced a research collaboration and license agreement with Janssen that will focus on the discovery and development of therapeutic antibodies in oncology.
The collaboration will utilise Immune Bioscience’s Nebula antibody discovery platform to advance oncology targets that historically have been a challenge for therapeutic development.
“The Nebula platform provides a new angle to antibody discovery with four families of technologies integrated within a single platform to deliver innovative antibody therapies in key disease areas,” said Frédéric Leduc, chief executive officer of Immune Biosolutions. “We are excited to be working with Janssen in this promising new area which we believe has the potential to transform and improve human health.”
Financial terms of the agreement were not disclosed.